Cover Image
市場調查報告書

全球氣喘市場

Global Asthma Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 311855
出版日期 內容資訊 英文 91 Pages
訂單完成後即時交付
價格
Back to Top
全球氣喘市場 Global Asthma Market 2014-2018
出版日期: 2014年09月03日 內容資訊: 英文 91 Pages
簡介

美國過敏氣喘免疫學會議(AAAAI)將氣喘分為4類:運動誘發性氣喘、過敏性氣喘、職業性氣喘,及兒童氣喘。美國氣喘過敏協會(AAFA)將氣喘分為2類:過敏性氣喘及非過敏性氣喘。氣喘是無法治癒之症,不過經由適時的診斷和持續定期的治療,可以控制。全球氣喘市場預計2013年∼2018年以4.50%的CAGR成長。

本報告提供全球氣喘市場相關調查分析、市場規模與成長率、市場趨勢、推動市場要素與課題、市場機會驗證、主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 市場區隔:各類藥物

  • 支氣管擴張劑
  • 白三烯拮抗劑
  • 肥大細胞穩定劑
  • 免疫抑制劑
  • LABA/ICS組合藥物

第8章 全球支氣管擴張劑市場

  • 市場概要
  • 市場規模與預測

第9章 全球白三烯拮抗劑市場

第10章 全球肥大細胞穩定劑市場

第11章 全球免疫抑制劑市場

第12章 全球ICS/LABA組合藥物市場

第13章 全球及其他的氣喘藥市場

第14章 地區區分

  • 全球氣喘市場:地區區分
  • 美國市場
  • 俄羅斯市場
  • 印度市場

第15章 發病率、得病率

第16章 購買標準

第17章 推動市場成長要素

第18章 推動因素與其影響

第19章 市場課題

第20章 推動因素與課題的影響

第21章 市場趨勢

第22章 趨勢與其影響

第23章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他卓越供應商

第24章 產品線的投資組合

第25章 主要供應商分析(產業概要、產業區分、產業策略、SWOT分析等)

  • AstraZeneca plc
  • Hoffmann La Roche
  • GlaxoSmithKline
  • Merck
  • Novartis

第26章 相關報告

圖表清單

目錄
Product Code: IRTNTR4048

About Asthma and its Categories

Asthma is a disease that affects the lungs and is characterized by wheezing, coughing, breathlessness, and chest tightness. It is a chronic ailment of the respiratory tract, which is caused by the obstruction of the flow of air and bronchospasms, where the muscles around the respiratory tract swell up. The disease is believed to be caused by genetic as well as environmental factors. The American Academy of Allergy Asthma and Immunology classifies asthma under four categories: exercise-induced asthma, allergic asthma, occupational asthma, and childhood asthma. The Asthma and Allergy Foundation of America classifies asthma into two categories: allergic asthma and non-allergic asthma. It is an incurable disease but can be controlled with the help of diagnosis at the right time, followed by regular therapy.

TechNavio's analysts forecast the Global Asthma Market to grow at a CAGR of 4.50 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Asthma market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various class of drugs used in the treatment of asthma:

  • Bronchodilators
  • Leukotriene antagonists
  • Mast cell stabilizers
  • Immunosuppressants

TechNavio's report, the Global Asthma Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Asthma Market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • AstraZeneca
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck
  • Novartis

Other Prominent Vendors

  • Abbott
  • Actavis
  • Amgen
  • AptarGroup
  • Astellas
  • Aurobindo
  • Biotest
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • Cipla
  • Cytos
  • Dainippon Sumitomo
  • Dr. Reddy's Laboratories
  • Glenmark
  • Medicinova
  • Mylan
  • Ono Pharmaceutical
  • Orchid Chemicals and Pharmaceuticals
  • Perrigo
  • Pfizer
  • Ranbaxy
  • Rottapharm Madaus
  • Skyepharma
  • Sosei
  • Sunovion
  • Teva
  • Theravance
  • Vectura

Market Driver

  • Rise in Prevalence of Disease

For a full, detailed list, view our report

Market Challenge

  • Unknown Etiology of Disease

For a full, detailed list, view our report

Market Trend

  • Popularity of Combination Therapies

For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Market Segmentation by Class of Drugs

  • 07.1. Bronchodilators
  • 07.2. Leukotriene Antagonists
  • 07.3. Mast Cell Stabilizers
  • 07.4. Immunosuppressants
  • 07.5. Combination of LABA/ICS

08. Global Bronchodilators Market

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast

09. Global Leukotriene Antagonists Market

  • 09.1. Market Overview
  • 09.2. Market Size and Forecast

10. Global Mast Cell Stabilizers Market

  • 10.1. Market Overview
  • 10.2. Market Size and Forecast

11. Global Immunosuppressants Market

  • 11.1. Market Overview
  • 11.2. Market Size and Forecast

12. Global Combination of ICS/LABA Market

  • 12.1. Market Overview
  • 12.2. Market Size and Forecast

13. Global Other Asthma Drugs Market

  • 13.1. Market Overview
  • 13.2. Market Size and Forecast

14. Geographical Segmentation

  • 14.1. Global Asthma Market by Geographical Segmentation 2013-2018
  • 14.2. Asthma Market in the US
    • 14.2.1. Market Overview
    • 14.2.2. Market Size and Forecast
  • 14.3. Asthma Market in the Russia
    • 14.3.1. Market Overview
    • 14.3.2. Market Size and Forecast
  • 14.4. Asthma Market in the India
    • 14.4.1. Market Overview
    • 14.4.2. Market Size and Forecast

15. Rate of Incidence and Prevalence

16. Buying Criteria

17. Market Growth Drivers

18. Drivers and their Impact

19. Market Challenges

20. Impact of Drivers and Challenges

21. Market Trends

22. Trends and their Impact

23. Vendor Landscape

  • 23.1. Competitive Scenario
    • 23.1.1. Key News
    • 23.1.2. Mergers and Acquisitions
  • 23.2. Market Share Analysis 2013
    • 23.2.1. AstraZeneca
    • 23.2.2. GlaxoSmithKline
    • 23.2.3. Merck
    • 23.2.4. Novartis
    • 23.2.5. Roche
  • 23.3. Other and Future Prominent Vendors

24. Pipeline Portfolio

25. Key Vendor Analysis

  • 25.1. AstraZeneca plc
    • 25.1.1. Key Facts
    • 25.1.2. Business Description
    • 25.1.3. Business Segmentation
    • 25.1.4. Business Strategy
    • 25.1.5. Revenue by Business Segmentation
    • 25.1.6. Revenue Comparison 2011-2013
    • 25.1.7. Sales Revenue by Geographical Segmentation
    • 25.1.8. Key Developments
    • 25.1.9. SWOT Analysis
  • 25.2. Hoffmann La Roche
    • 25.2.1. Key Facts
    • 25.2.2. Business Overview
    • 25.2.3. Business Segmentation by Revenue 2013
    • 25.2.4. Business Segmentation by Revenue 2012 and 2013
    • 25.2.5. Geographical Segmentation by Revenue 2013
    • 25.2.6. Business Strategy
    • 25.2.7. Recent Developments
    • 25.2.8. SWOT Analysis
  • 25.3. GlaxoSmithKline
    • 25.3.1. Key Facts
    • 25.3.2. Business Overview
    • 25.3.3. Business Segmentation
    • 25.3.4. Business Segmentation by Revenue 2012 and 2013
    • 25.3.5. Sales by Geography
    • 25.3.6. Pipeline Products
    • 25.3.7. Business Strategy
    • 25.3.8. Key Information
    • 25.3.9. SWOT Analysis
  • 25.4. Merck
    • 25.4.1. Key Facts
    • 25.4.2. Business Overview
    • 25.4.3. Business Segmentation by Revenue 2013
    • 25.4.4. Business Segmentation by Revenue 2012 and 2013
    • 25.4.5. Sales by Geography
    • 25.4.6. Business Strategy
    • 25.4.7. Key Developments
    • 25.4.8. SWOT Analysis
  • 25.5. Novartis
    • 25.5.1. Key Facts
    • 25.5.2. Business Overview
    • 25.5.3. Business Segmentation by Revenue 2013
    • 25.5.4. Business Segmentation by Revenue 2012 and 2013
    • 25.5.5. Sales by Geography
    • 25.5.6. Business Strategy
    • 25.5.7. Key Developments
    • 25.5.8. SWOT Analysis

26. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Asthma Market 2014-2018 (US$ million)
  • Exhibit 3: Global Asthma Market Segmentation by Class of Drugs
  • Exhibit 4: Global Asthma Market Segmentation by Class of Drugs 2013
  • Exhibit 5: Global Bronchodilators Market 2013-2018 (US$ million)
  • Exhibit 6: Global Leukotriene Antagonists Market 2013-2018 (US$ million)
  • Exhibit 7: Global Mast Cell Stabilizers Market 2013-2018 (US$ million)
  • Exhibit 8: Global Immunosuppressants Market 2013-2018 (US$ million)
  • Exhibit 9: Global Combination of ICS/LABA Market 2013-2018 (US$ million)
  • Exhibit 10: Global Other Asthma Drugs Market 2013-2018 (US$ million)
  • Exhibit 11: Global Asthma Market by Geographical Segmentation 2013
  • Exhibit 12: Asthma Market in the US 2013-2018 (US$ million)
  • Exhibit 13: Asthma Market in Russia 2013-2018(US$ million)
  • Exhibit 14: Asthma Market in India 2013-2018 (US$ million)
  • Exhibit 15: Prescription Trend Chart of the Popular Asthma Drugs in the US 2013
  • Exhibit 16: Global Asthma Market Share Analysis 2013
  • Exhibit 17: Global Sales of Symbicort 2009-2012 (in US$ million)
  • Exhibit 18: Geography-wise Sales of Symbicort 2009-2012 (US$ million)
  • Exhibit 19: Global Sales of Pulmicort 2009-2012 (US$ million)
  • Exhibit 20: Geography-wise Sales of Pulmicort 2009-2012 (US$ million)
  • Exhibit 21: Global Sales of Singulair 2011-2013 (US$ million)
  • Exhibit 22: Global Sales of Dulera 2011-2013 (US$ million)
  • Exhibit 23: Global Sales Forecast of Dulera 2013-2016 (US$ million)
  • Exhibit 24: Pipeline Snapshot of Asthma Drugs
  • Exhibit 25: Sales Forecast of QMF-149 2016-2018 (US$ million)
  • Exhibit 26: AstraZeneca plc: Business Segmentation
  • Exhibit 27: AstraZeneca plc: Revenue by Business Segmentation2013
  • Exhibit 28: AstraZeneca plc: Revenue by Business Segmentation 2011-2013 (US$ billion)
  • Exhibit 29: AstraZeneca plc: Sales Revenue by Geographical Segmentation 2013
  • Exhibit 30: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
  • Exhibit 31: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 32: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals Division)
  • Exhibit 33: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics Division)
  • Exhibit 34: GlaxoSmithKline plc: Business Segmentation 2013
  • Exhibit 35: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 36: GlaxoSmithKline plc: Sales by Geography 2013
  • Exhibit 37: GlaxoSmithKline plc: Pipeline Products 2013
  • Exhibit 38: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 39: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 40: Merck & Co. Inc.: Sales by Geography 2013
  • Exhibit 41: Novartis AG: Business Segmentation by Revenue 2013
  • Exhibit 42: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 43: Novartis AG: Sales by Geography 2013
Back to Top